Swapnil Malekar

Stock Analyst at Piper Sandler

(0.52)

# 3,059

Out of 4,433 analysts

2

Total ratings

50%

Success rate

-11.85%

Average return

Main Sectors:

Top Industries:

2 Stocks

	Stock	Action	Price Target	Current	Upside	Ratings	Updated
	IMRX Immuneering	Initiates: Overweight	$41	$1.54	+2,562.34%	1	Jan 7, 2022
	NTLA Intellia Therapeutics	Initiates: Overweight	$171	$26.17	+553.42%	1	Jan 7, 2022

Immuneering

Jan 7, 2022

Initiates: Overweight

Price Target: $41

Current: $1.54

Upside: +2,562.34%

Intellia Therapeutics

Jan 7, 2022

Initiates: Overweight

Price Target: $171

Current: $26.17

Upside: +553.42%